127 related articles for article (PubMed ID: 37642572)
1. Identifying Proliferative Hepatocellular Carcinoma at Pretreatment CT: Implications for Therapeutic Outcomes after Transarterial Chemoembolization.
Bao Y; Li JX; Zhou P; Tong Y; Wang LZ; Chang DH; Cai WW; Wen L; Liu J; Xiao YD
Radiology; 2023 Aug; 308(2):e230457. PubMed ID: 37642572
[TBL] [Abstract][Full Text] [Related]
2. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
Chen S; Peng Z; Zhang Y; Chen M; Li J; Guo R; Li J; Li B; Mei J; Feng S; Kuang M
Radiology; 2021 Mar; 298(3):680-692. PubMed ID: 33464183
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
[TBL] [Abstract][Full Text] [Related]
5. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery.
Kang HJ; Kim H; Lee DH; Hur BY; Hwang YJ; Suh KS; Han JK
Radiology; 2021 Sep; 300(3):572-582. PubMed ID: 34227881
[TBL] [Abstract][Full Text] [Related]
6. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
7. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW
Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144
[TBL] [Abstract][Full Text] [Related]
10. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.
Deng Z; Zhang W; Peng J; Gao L; Zhang C; Lei K; Gong J; Xiong B
Cardiovasc Intervent Radiol; 2024 May; 47(5):592-603. PubMed ID: 38605220
[TBL] [Abstract][Full Text] [Related]
11. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response.
Dioguardi Burgio M; Sartoris R; Libotean C; Zappa M; Sibert A; Vilgrain V; Ronot M
Cancer Imaging; 2019 Nov; 19(1):75. PubMed ID: 31730491
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE.
Hu B; Zhong BY; Zhang L; Dai C; Li W; Shen J; Huang P; Zhang S; Li Z; Ni CF
Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1460-1467. PubMed ID: 32500251
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
14. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
15. Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization.
Bannangkoon K; Hongsakul K; Tubtawee T
BMC Gastroenterol; 2021 Nov; 21(1):419. PubMed ID: 34749658
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
17. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Zhang Y; Zhang M; Chen M; Mei J; Xu L; Guo R; Lin X; Li J; Peng Z
JAMA Netw Open; 2018 Oct; 1(6):e183213. PubMed ID: 30646226
[TBL] [Abstract][Full Text] [Related]
18. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
[TBL] [Abstract][Full Text] [Related]
19. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
20. Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization.
Yu SCH; Chan SL; Lee KF; Hui JWY; Hui EP; Chu CM; Chan AW; Cheung S; Li L; Wong J; Yeo WMM
Radiology; 2018 Apr; 287(1):340-348. PubMed ID: 29272212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
